Peter Houghton J. PhD

Peter Houghton J. PhD
ProfessorCollege of MedicinePeter.Houghton@nationwidechildrens.org
Children's Hospital 700 Children's Drive Columbus OH 43205
Phone:(614) 355-2670Fax:
  • Administrative
  • Translational Therapeutics

Research Description

The Houghton Lab is focused on understanding the basic biology of childhood solid tumors, largely sarcoma. Dr. Houghton has identified a chromosomal rearrangement in rhabdomyosarcoma that leads to downstream over-expression of insulin-like growth factor 2 (IGF2) ligand. His lab is working to interpret the signaling pathway and is developing therapeutic approaches to block IGF signaling in rhabdomyosarcoma, Wilms’ tumors, neuroblastoma, Ewing sarcomas, and a range of other tumors.

Current Publications

  • Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RBInitial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1493-6 8/1/2014
  • Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1486-9 8/1/2014
  • Suryani S, Carol H, Ni Chonghaile T, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Moradi Manesh D, Kurmasheva RT, Billups CA, Kaplan W, Letai A, Bourquin JP, Houghton P, Smith MA, Lock RBCELL AND MOLECULAR DETERMINANTS OF IN VIVO EFFICACY OF THE BH3 MIMETIC ABT-263 AGAINST PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS.Clin Cancer Res in press 7/10/2014
  • McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM, Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JMA phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.Pediatr Blood Cancer 61 1246-51 7/1/2014
  • Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.Pediatr Blood Cancer in press 6/9/2014
  • Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M, Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ESToward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma.Clin Cancer Res in press 5/6/2014
  • Smith MA, Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJInitial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Pediatr Blood Cancer 61 922-4 5/1/2014
  • Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, Franssen GM, Flucke UE, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WTTemsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.Int J Cancer in press 4/26/2014
  • Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran KHO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.Cancer Res 74 2316-27 4/15/2014
  • Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam Hp53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.J Biol Chem 289 4083-94 2/14/2014
  • Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MAInitial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 380-2 2/1/2014
  • Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R, Carol HInitial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 245-52 2/1/2014
  • Raffel C, Studebaker AW, Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz ATreatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.BMC Cancer 14 206 1/1/2014
  • Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam HΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis.Cancer Res 74 320-9 1/1/2014
  • Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 158-64 1/1/2014
  • Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ, Bid HKDevelopment, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Clin Cancer Res 19 6716-29 12/15/2013
  • Hsu SH, Wang B, Kutay H, Bid H, Shreve J, Zhang X, Costinean S, Bratasz A, Houghton P, Ghoshal KHepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.Am J Pathol 183 1719-30 12/1/2013
  • Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MAInitial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Pediatr Blood Cancer 60 1860-7 11/1/2013
  • Houghton PJNew insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?Expert Rev Anticancer Ther 13 1135-8 10/1/2013
  • Bid HK, Roberts RD, Manchanda PK, Houghton PJRAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.Mol Cancer Ther 12 1925-34 10/1/2013
  • Gorlick R, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JMInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.Pediatr Blood Cancer 60 1325-32 8/1/2013
  • Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC, Balkhi MY, Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJmiR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.Sci Signal 6 ra63 7/30/2013
  • Shen C, Houghton PJThe mTOR pathway negatively controls ATM by up-regulating miRNAs.Proc Natl Acad Sci U S A 110 11869-74 7/16/2013
  • Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60 E42-5 7/1/2013
  • Smith MA, Houghton PA proposal regarding reporting of in vitro testing results.Clin Cancer Res 19 2828-33 6/1/2013
  • Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJRegulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.Cancer Res 73 3393-401 6/1/2013
  • Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJDual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.Clin Cancer Res 19 2984-94 6/1/2013
  • Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Houghton PJ, Smith MA, Keir ST, Maris JM, Billups CAInitial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.Pediatr Blood Cancer 60 791-8 5/1/2013
  • Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick RInitial testing (stage 1) of temozolomide by the pediatric preclinical testing program.Pediatr Blood Cancer 60 783-90 5/1/2013
  • Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, Lock RBThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Clin Cancer Res 19 1795-805 4/1/2013
  • Houghton PJ, Smith MA, Lock RB, Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RTInitial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60 633-41 4/1/2013
  • Kaplon R, Hadziahmetovic M, Sommerfeld J, Bondra K, Lu L, Leasure J, Nguyen P, McHugh K, Li N, Chronowski C, Sebastian N, Singh M, Kurmasheva R, Houghton P, Pelloski CEThe application of radiation therapy to the Pediatric Preclinical Testing Program (PPTP): results of a pilot study in rhabdomyosarcoma.Pediatr Blood Cancer 60 377-82 3/1/2013
  • Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MAInitial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.Pediatr Blood Cancer 59 1266-74 12/15/2012
  • Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA, Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJInitial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 59 749-52 10/1/2012
  • Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJEvaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Pediatr Blood Cancer 59 753-5 10/1/2012
  • Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MATesting of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59 518-24 9/1/2012
  • Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MAInitial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59 586-8 9/1/2012
  • Furman WL, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM, McGregor LM, McCarville MB, Onciu M, Davidoff AMA single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Invest New Drugs 30 1660-70 8/1/2012
  • Wu J, Smith PG, Yu J, Houghton PJ, Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CLInitial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.Pediatr Blood Cancer 59 246-53 8/1/2012
  • Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Houghton PJ, Arts J, Bashir T, Janicot M, Kurmasheva RTInitial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer 59 329-32 8/1/2012
  • Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Kurmasheva RT, Houghton PJ, Arts J, Bashir T, Janicot MInitial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer 59 329-32 8/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu